Please login to the form below

Not currently logged in

Athenex expands global leadership team

Dr Simon Pedder and Raymond Yeung join the pharmaceutical firm

Global specialty oncology pharmaceutical company Athenex has appointed Dr Simon Pedder and Raymond Yeung to its global leadership team.

Based in the US, Dr Pedder joins as vice president of corporate strategy and business development.

He brings over 25 years of executive management experience in drug development, including as vice president of oncology pharma business at Hoffman-LaRoche, vice president and head of drug development at Shearwater Corporation and most recently as president and chief executive officer for Cellectar Biosciences.

Dr Pedder said: “Athenex has a very strong executive management team … [and] coupled with their unique business model and deep oncology portfolio, Athenex is going to be a leader in the US and China, reshaping traditional treatment options for cancer patients.

“I am looking forward to joining their leadership team to further their business and scientific strategies.”

Meanwhile, Raymond Yeung joins Athenex's Hong Kong office as its new senior director and deputy head of clinical research and regulatory affairs, Asia-Pacific.

Prior to joining the oncology specialist firm, Yeung held several senior management positions in preclinical and clinical development, including managing director of Albany Molecular Research Inc, general manager at Fortune Pharmacal and director of Asia-Pacific at MSD Pharma Services.

Yeung said: “I am delighted to come out of retirement to work with [Athenex's] leadership team to contribute towards the development of new medicine to help patients and also to bridge the biotechnology/pharmaceutical space between the US and China.”

15th February 2016

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

When is it time to rebrand?
The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....